Kornimate/medical-research-clean huggingface dataset:
geniculate nerve block versus adductor canal block for acl reconstruction surgery

Conditions: ACL Tear; Pain, Postoperative

Summary: anterior cruciate ligament repair (acl) surgery presents moderate to severe pain during the inmediate postoperative period and the first days after surgery. in addition, due to the interest of surgeons and patients for early reinstatement, the use of blockages that decrease the strength of the quadriceps is avoided. therefore, in recent years, the adductor canal block (acb) has been used for postoperative analgesia with variable results. genicular nerve block (gnb) has been used for pain management in patients with knee osteoarthritis and recently in knee arthroplasty surgery with results similar to the local anesthetic infiltration techniques by the surgeon (lia). considering their good results in these patients in addition to being a 100% sensitive block without risk of motor involvement. the investigators proposed this experimental study to evaluate tha analgesic efficacy of the genicular nerve block (gnb) compared with the adductor canal block (acb) for the anterior cruciate ligament (acl) repair surgery.

participants scheduled to undergo anterior cruciate ligament reconstruction under general anaesthesia will be allocated to two groups: adductor canal block or genicular nerve block- the adductor canal block will be performed by the anaesthesiologist under ultrasound guidance prior the surgery, after inducction , using 20 mls ropivacaine 0.2%. the genicular nerve block will be performed by the anaesthesiologist under ultrasound guidance prior the surgery, after inducction , using 20 mls ropivacaine 0.2% in total. postoperative analgesia will include analgesia (dexketoprofen 75 mg during first 24 hours), acetomiophen 1 gr every 8 hours and tramadol for rescue pain.

Eligibility criteria:
inclusion criteria: * patients from 18 to 50 years old scheduled to undergo anterior cruciate ligament reconstruction exclusion criteria: * peripheral neuropathy * pre-existing femoral neuropathy * diabetes mellitus * alcoholism * drug addiction * cancer with chemotherapy * chronic pain state * negative of the patient to participate in the study.
the effect of environmental factors on gastric cancer based on macrogenome

Conditions: Gastric Cancers; Air Pollution

Summary: the objectives of this study were to clarify how environmental factors such as air pollution affect the occurrence and development of gastric cancer; to identify patient-specific macrogenomic markers of gastric cancer; and to investigate the mechanism of gastric cancer development based on environmental factors and macrogenomic data.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years; * patients with preoperative diagnosis of gastric cancer confirmed by pathologic biopsy; * no chemotherapy, radiotherapy, targeted and immunotherapy, etc. before enrollment; * willing to participate in the study and sign the informed consent form; * complete clinical data. exclusion criteria: * concurrent primary malignant tumor other than gastric cancer; * patients with systemic diseases, such as severe cardiopulmonary; * insufficiency, that affect the choice of treatment plan; * not suitable for enrollment as assessed by the investigator; * incomplete clinical data.

Keywords: gastric cancer macrogenome environmental pollution air pollution
talonavicular arthrodesis and surgical treatment of ankle and varus foot

Conditions: Orthopedic Equine Varus Deformity

Summary: this study should refine our surgical indications and to establish a decision tree of medical and surgical treatment of this common and troublesome strain functionally which is equino-varus.


Eligibility criteria:
inclusion criteria: * hemiparesis secondary to a lesion of the central nervous system, regardless of the etiology dated within 6 months * orthopedic equine-varus deformity of the foot and ankle requiring surgery * patient able to move by walking preoperatively at least 2 meters with or without technical assistance or may earn postoperative walking ability exclusion criteria: * history of foot surgery the side to be operated * significant deformation set foot and ankle (requiring treatment with triple arthrodesis) * bilateral surgery * progressive neurological disease * dystonic movements or movement disorders * realization of a botulinum toxin injection in the 6 months preceding gesture * important cognitive impairment

Keywords: hemiparesis deformity of the foot and ankle
predictors of lymphedema following breast cancer surgery

Conditions: Breast Cancer; Lymphedema

Summary: the purpose of this study evaluate which factors play a role in lymphedema development among women who have had axillary surgery for breast cancer. potential risk factors for women who have developed lymphedema will be compared to risk factors among women who have not developed lymphedema after breast cancer surgery.

surgery for breast cancer includes removal of the breast tumor along with the axillary lymph nodes. the status of these nodes helps clinicians determine prognosis and guides treatment decisions. unfortunately, a relatively common side effect following axillary lymph node dissection is upper-extremity lymphedema. the purpose of this study is to identify risk factors for lymphedema among women who have had axillary surgery for breast cancer. specific aims include identifying risk factors for lymphedema and comparing quality of life (qol) ratings for women who have and do not have lymphedema. a case-control study will be conducted with enrollment of 200 participants. cases will be identified at their lymphedema consult in the physical therapy centers. using the oncology registry, controls will include patients who have had breast cancer surgery and have not developed lymphedema. the severity of lymphedema and interference with daily life will be assessed with the measure of arm symptom survey (mass), a patient-completed survey, and qol will be collected with the sf-36. treatment risk factors including previous surgery, radiotherapy and chemotherapy will be obtained from oncology registry data. this study will determine which factors play a role in lymphedema development.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of lymphedema * axillary node surgery by sentinel node or axillary node dissection * no known metastatic disease in the axilla * able and willing to give informed consent

Keywords: breast cancer lymphedema quality of life
comparison of functional outcome between bqt and sbht acl reconstruction

Conditions: Sports Injury; Anterior Cruciate Ligament Rupture

Summary: acl rupture has a high morbidity in productive-age population. the increasing incidence and proper management has become a point of interest in the musculoskeletal sport injury. choosing the best graft has become the main focus in searching for a better outcome regarding acl reconstruction in these patient population. currently, single bundle hamstring tendon (sbht) autograft was preferred in asian population compared to bone quadriceps tendon (bqt) autograft. however, there are some problems such as smaller size, as well as diameter, of sbht. this study is focused on evaluation of the clinical outcome between bqt and sbht in arthroscopic-assisted acl reconstruction patients.

in this prospective cohort study, 30 subjects were divided into 2 groups (bqt and sbht). sampling was taken between february 2016-2017 (1 year) in one orthopaedic center. the instruments used for evaluation are rolimeter and pro questionnaires (ikdc, tegner-lysholm, and koos) with data mining between 1 month, 3 months, and 6 months post operation. to obtain a valid and accountable research data, the investigators collected the information based on 2 parameters and then crosschecked the results. after clinical data was obtained, the investigators translate the results into a statistical data using spss ver.24 and simplified the data for national registry and academic purposes. according to previous studies, and research hypothesis, functional outcome of patient undergoing arthroscopic-assisted acl reconstruction is better in bqt group compared to sbht group, both in subjective and objective parameters given.

Eligibility criteria:
inclusion criteria: * unilateral, total rupture of acl * procedure performed by the same surgeon * age of subjects between 15-40 years old exclusion criteria: * multiligamentous injury * bilateral acl ruptures * ligamentous laxity * prior knee ligamentous surgery

Keywords: acl reconstruction arthroscopic-assisted bqt sbht
the effect of phacoemulsification on intraocular pressure in primary angle closure glaucoma (pacg) patients at phanat nikhom hospital, chonburi province

Conditions: Primary Angle Closure Glaucoma

Summary: background: primary angle closure glaucoma (pacg) is one of a leading cause of blindness worldwide including thailand. this problem impact to the overall health of people and health care system. treatment guidelines of each stage is differenced. therefore, factors that affect to treatment should be explored to plan for taking care patients in the future. objectives: the study aimed to examine the effects of cataract surgery by phaco- emulsification on intraocular pressure and to determine the factors associated with intraocular pressure among primary angle closure glaucoma patients.

background: primary angle closure glaucoma (pacg) is one of a leading cause of blindness worldwide including thailand. this problem impact to the overall health of people and health care system. treatment guidelines of each stage is differenced. therefore, factors that affect to treatment should be explored to plan for taking care patients in the future. objectives: the study aimed to examine the effects of cataract surgery by phaco- emulsification on intraocular pressure and to determine the factors associated with intraocular pressure among primary angle closure glaucoma patients. methods: a retrospective descriptive study was conducted in 121 patients with primary angle closure glaucoma who underwent phacoemulsification between october 1st 2017 and september 30th 2022. the preoperative and postoperative record form were used as the research instrument. visual acuity, intraocular pressure, the number of glaucoma medications and ocular biometric parameters were collected. the descriptive statistics, paired sample t-test, repeated measures anova and multiple linear regression were used to analyze the outcomes. a p-value \< 0.05 was considered statistically significant.

Eligibility criteria:
inclusion criteria: * age more 18 years old and not complication of cataract surgey exclusion criteria: * other eye diseases affect to visual defect * previous ocular surgery * complication of cataract surgery * data record incomplete
link hepatitis c notifications to treatment in tasmania

Conditions: Hepatitis C

Summary: this project will utilise the notification process as a point of intervention to work with primary practitioners (gp) by contacting them directly when a notification of hepatitis c exposure is received by the tasmanian department of health (doh). a designated role will exist within doh of a specialist hcv health worker to contact gps to provide supported assistance in the process of the follow up hepatitis c diagnoses with patients. the study will evaluate whether active follow up of providers with enhanced case management is effective in having patients linked to hepatitis c treatment compared to current standard of care of surveillance for new notifications. the study will also compare the cost-effectiveness of this approach compared to current standard of care after one of their patients is notified with a positive hepatitis c antibody result.


Eligibility criteria:
inclusion criteria: * general practitioners (gp) who have requested a hepatitis c test that leads to new or repeat notification to the tasmanian department of health exclusion criteria: * not based in tasmania * practitioner from correctional service * specialist * nurse practitioner who initiated test * sexual health service doctor * family planning * trainee
tissue oxygen saturation for esophagectomy

Conditions: Esophageal Neoplasms; Esophagostomy Complication; Anastomotic Leak; Oxygen Deficiency

Summary: tissue oxygen saturation monitoring was a useful indicator of blood flow insufficiency in the gastric tube leading to anastomotic leakage during radical esophagectomy.

one cause of anastomotic leakage after radical esophagectomy is blood flow insufficiency at the cervical anastomosis site. . eighteen patients, who underwent radical esophagectomy with gastric tube reconstruction, were studied. the regional tissue oxygen saturation (rso2) was measured at the tip (point pre 0) and 2, 4, and 6 cm on the anal side of the tip (point pre 1, pre 2, and pre 3, respectively) before the gastric tube was raised to the cervical site through the retrosternal route. after that, rso2 was measured at the tip, 2 and 4 cm on the anal side of the tip (points post 0, post 1, and post 2), the actual anastomotic site (point an), and the chest skin as an indicator of whole-body oxygenation . the relationship between rso2 scores and the rate of anastomotic leakage was determined.

Eligibility criteria:
inclusion criteria: * patients who underwent esophagectomy with gastric tube reconstruction from november 2020 to march 2021. exclusion criteria: * patients who underwent esophagectomy with jejunum or colon reconstruction. patients who underwent two-stage operation.

Keywords: esophagectomy, tissue oxygen saturation, gastric tube, anastomotic leakage
incremental hemodialysis as a starting way of renal replacement therapy

Conditions: Chronic Renal Failure

Summary: the hemodialysis unit of the hospital ramon y cajal is a pioneer in the implementation of a program of incremental hemodialysis, starting with two sessions a week in patients with residual renal function. the main objective is to compare whether the initiation of hemodialysis with two sessions a week over conventional pattern of initiation of three sessions a week better preserves residual renal function.

the primary specific objective is to assess the loss of renal function defined as 24 hours diuresis less than 100 ml at 12 months of starting treatment. secondary objectives are: erythropoietin dose, concentration of beta 2-microglobulin, p-cresol, fenol, the state of hydration and nutrition, adverse effects, hospital admissions, mortality and quality of life, comparing both arms of treatment. design: multicenter randomized clinical trial. randomization will be performed by an external agent that guarantees an homogeneous balance between both arms. the randomization sequence will not be available for the investigators responsible of the patients. inclusion criteria: patients starting hemodialysis that maintain residual diuresis and urea clearance greater than or equal to 2.5 ml / min with a minimum follow-up of one year. exclusion criteria: anuric patients, patients with acute renal failure and patients who start hemodialysis after having going through a renal transplant. the variables that will be analyzed are 24h diuresis, urea clearance, creatinin clearance, haemoglobin, leukocytes, platelets, creatinin, urea, na, k, albumin, prealbumin, ca, p, pth, pcr, ferritin, b2microglobulin, bnp, kt/v, erythropoietin dose, state of hydratation and life quality. sample size should be of 42 patients on each arm of treatment to obtain a 95% confidence (α=0,05) and a 80% of statistical power (β=0,20). the normality of the data will be analyzed with kolmogorov-smirnov test which will allow to use parametric tests (t-student) or non-parametric tests (u-mann-whitney). association of categoric variables of both arms will be analyzed with chi2 test, or using fisher statistic. loss of renal function will be analyzed up to 12 months and time studies will be performed through non-parametric test (kaplan-meier), obtaining the estimated probability of loss of renal function in both arms and comparing survival functions through "log-rank" statistic. the demonstration of efficacy and safety through a clinical trial would spread this clinical practice in the nephrology community and therefore in our national health system.

Eligibility criteria:
inclusion criteria: * subjects starting renal replacement therapy from january 2017 to june 2018. * subjects who consent to sign the informed consent form. * subject who maintain residual diuresis and urea clearance equal or superior to 2,5 ml/min. exclusion criteria: * anuric patients. * patients with acute renal failure. * patients who revoke the informed consent form. * patients who start hemodialysis after having going through a renal transplant.
zimmer® motionloc® in distal tibia fractures

Conditions: Distal Tibia Fractures

Summary: the objective of this observational prospective study is to systematically document the clinical outcomes of zimmer motionloc screws for periarticular locking plate system applied to distal tibia fracture treatment and confirm safety and performance of the screws.

primary endpoint: * radiographic \& clinical fracture healing at 3 months post-surgery. secondary endpoints: * complications * radiologic \& clinical fracture healing at 6 weeks, 3, 6, and 12 months post-surgery. * callus size \& distribution at 6 weeks, 3, 6, and 12 months post-surgery. radiologic fracture healing is defined as bridging of three of the four cortices as seen on x-ray/ct. clinical healing will be assessed using the function index for trauma (fix-it). the fix-it instrument quantifies clinical healing by assessing weight-bearing and fracture site pain on an ordinal scale. it has been initially validated in patients with tibia and femur fractures. callus size of the anterior, posterior, and medial aspect will be assessed for each time point using a validated and published computational method.

Eligibility criteria:
inclusion criteria: * with or without fibula fracture involvement (treated or not treated by osteosynthesis) * close or open fractures gustilo type i * unilateral or bilateral fractures * patients who are capable of understanding the doctor's explanations, following his instructions and are able to participate in the follow-up program. * patients who give written consent to take part in the study by signing the "patient consent form". exclusion criteria: * delay of surgery for more than two weeks. * open fractures gustilo type ii \& iii * history of infection of the affected extremity * non-ambulatory patients * planned fixation strategy includes interfragmentary lag screw fixation of non-articular fractures. * addition of bone graft, bone graft substitute or bone morphogenetic protein (bmp). * immobilization with plaster. * likely problems with maintaining follow-up program (e.g. patients with no fixed address, plans to move during course of study) * not expected to survive the duration of follow-up program. * patients known to be pregnant or breastfeeding. * patients who are unwilling or unable to give consent.

Keywords: distal tibia fracture screw
evaluation of luminal expansion following stenting of femoro-popliteal occlusive disease

Conditions: Femoropopliteal Stenosis

Summary: the primary goal of this trial is to compare prospectively stent opening of supera (idev technologies) versus a reference stent (lifestent, bard medical) using c-arm ct. a secondary goal is to correlate stent opening with stent patency as documented by doppler ultrasound at one year post implantation.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * patient (or legally authorized representative) must give a written informed consent. * symptomatic peripheral-artery disease with moderate or severe intermittent claudication and failure of medical treatment (rutherford stage 2,3) or chronic critical limb ischemia with pain while the patient is at rest (rutherford stage 4) or chronic critical limb ischemia with ischemic ulcers (rutherford stage 5, 6) and stenosis of more than 70 percent or occlusion of the ipsilateral superficial femoral artery and/or proximal popliteal artery with a target-lesion length of ≥ 8 and ≤ 20 cm and at least one patent (less than 50 percent stenosed) tibioperoneal runoff vessel (tasc a,b,c lesions)25. proximal popliteal artery is defined as the popliteal artery above the joint line. the distal portion of the lesion should be located at least 4 cm above the joint line and the distal end of the stent 2 cm above the joint line. * abi ≤ 0.9 at rest. toe-brachial index (tbi) may be used if abi is inadequate. * lesion with a calcification percentage of at least 25% based on cta evaluation (within 6 months of patient enrolment) exclusion criteria: * acute critical limb ischemia * untreated inflow disease of the ipsilateral pelvic arteries (more than 50 percent stenosis or occlusion). * renal failure, creatinine clearance \< 50 µmol /l * severe allergy to iodine contrast * patients with uncorrected bleeding disorders or patients who cannot receive anticoagulation or antiplatelet aggregation therapy * lesions \ 20 cm in length * calcification volume of less than 25%
study of bosutinib with capecitabine in solid tumors and locally advanced or metastatic breast cancer

Conditions: Advanced Breast Cancer (Parts 1 and 2); Advanced Pancreatic Cancer (Part 1); Advanced Colorectal Cancer (Part 1); Advanced Cholangiocarcinoma (Part 1); Advanced Glioblastoma Multiforme (Part 1)

Summary: this is a research study in 2 parts assessing the following parameters of the combination of the study drug called bosutinib, and a drug called capecitabine: the safety, how well the subject's body handles the study drug, and preliminary anti-tumor activity as treatment for different types of cancers in part 1, and breast cancer only in part 2. in part 1, subjects will receive bosutinib and capecitabine daily at different dose levels of each drug in order to determine the highest tolerated dose of the combination study treatment. in part 2, subjects will receive bosutinib and capecitabine at this highest tolerated dose to see how well the study treatment works to treat breast cancer. in addition, genetic research testing (research analyses involving genes and gene products) will be performed on biological samples from subjects.

the study was prematurely discontinued following part 1 evaluation, when the sponsor concluded that further translational biomarker analyses were needed to better define the breast tumor biomarkers that predict sensitivity to src family kinase inhibitors. thus the sponsor made a determination to stop the study after part 1 as communicated to investigators on 02dec2010 . no subjects were enrolled into part 2 of this study. the study was not terminated due to safety reasons.

Eligibility criteria:
inclusion criteria: part 1: * ages eligible for study: 18 years or older. * male and female. * confirmed pathologic diagnosis of advanced breast cancer or pancreatic cancer or colorectal cancer or cholangiocarcinoma or glioblastoma not curable with available therapies, for whom bosutinib plus capecitabine is a reasonable treatment option. part 2: * ages eligible for study: 18 years or older. * female. * confirmed pathologic diagnosis of locally advanced or metastatic breast cancer, or loco-regional recurrent breast cancer that is not amenable to curative treatment with surgery or radiotherapy. * documented er+ and/or pgr+/erbb2- or er-/pgr-/erbb2- tumor based upon recently analyzed biopsy. exclusion criteria: part 1: * prior bosutinib, or any other prior src inhibitor. * prior chemotherapy with capecitabine or 5-fu for the treatment of metastatic disease is allowed unless patient stopped therapy for toxicity. part 2: * prior bosutinib, or any other prior src inhibitor prior chemotherapy with capecitabine or 5-fu for the treatment of metastatic disease. * prior chemotherapy with capecitabine or 5-fu for adjuvant chemotherapy within the past 12 months. * erbb2+ breast cancer.

Keywords: phase 1/2 2-part study bosutinib and capecitabine